Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $25
Press Release: Evolus to Report First Quarter Financial Results on May 7, 2025
Evolus (EOLS) Receives a Buy From Mizuho Securities
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BTIG Initiates Evolus(EOLS.US) With Buy Rating, Announces Target Price $21
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
BTIG Initiates Coverage On Evolus With Buy Rating, Announces Price Target of $21
BriaCell BCTX Phase 2 Data; Evolus EOLS Product Launch
Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse Injectable Hyaluronic Acid Gels
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Not Many Are Piling Into Evolus, Inc. (NASDAQ:EOLS) Stock Yet As It Plummets 26%
H.C. Wainwright Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $27
Evolus Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Needham Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $22
Breaking Down Evolus: 8 Analysts Share Their Views
Express News | Needham Reiterates Buy on Evolus, Maintains $22 Price Target
Evolus Analyst Ratings
Optimistic Outlook for Evolus: Buy Rating Backed by Strategic Positioning and Strong Product Performance
Evolus, Inc. (NASDAQ:EOLS): Is Breakeven Near?